Major Shareholder Tenders All Shares into Servier Acquisition Offer
DAWN has more than doubled off its 52-week low of $5.635 on light trading volume (0.2× avg).
Summary
Access Industries, a significant shareholder, has tendered all of its 12.52% stake in Day One Biopharmaceuticals into Servier's $21.50 per share cash tender offer, confirming its support for the acquisition.
Key Events · M&A and Partnerships · DAWN
-
Major Shareholder Tenders Shares
Access Industries, holding 12.52% of Day One Biopharmaceuticals, has tendered all 12,929,322 shares into Servier's tender offer.
-
Confirms Acquisition Progress
This action, valued at approximately $278 million, reinforces the progress of Servier's acquisition of Day One Biopharmaceuticals at $21.50 per share.
-
Follows Regulatory Approval
The tendering of shares occurs just days after the FTC granted early termination of the HSR waiting period, satisfying a major regulatory condition for the acquisition.
Analysis · DAWN · Life Sciences
This Schedule 13D/A filing confirms that Access Industries, a major investor holding 12.52% of Day One Biopharmaceuticals' common stock, has tendered all of its shares into the ongoing acquisition offer by Servier. This action, valued at approximately $278 million, signals strong shareholder support for the $21.50 per share cash tender offer. Coming shortly after the satisfaction of key regulatory conditions for the acquisition, this filing provides further assurance that the transaction is progressing towards completion. Investors should view this as a positive indicator for the deal's finalization.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DAWN was trading at $21.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $5.64 to $21.49. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.